Difference between revisions of "Amatuximab (MORAb-009)"
Jump to navigation
Jump to search
m |
m |
||
| Line 1: | Line 1: | ||
=Mechanism of action= | =Mechanism of action= | ||
Anti-mesothelin monoclonal antibody | Anti-mesothelin monoclonal antibody | ||
| + | |||
| + | =Preliminary data= | ||
| + | ==[[Mesothelioma]]== | ||
| + | # Hassan R, Kindler HL, Jahan T, Bazhenova L, Reck M, Thomas A, Pastan I, Parno J, O'Shannessy DJ, Fatato P, Maltzman JD, Wallin BA. Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma. Clin Cancer Res. 2014 Dec 1;20(23):5927-36. Epub 2014 Sep 17. [http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4252585/ link to PMC article] [http://www.ncbi.nlm.nih.gov/pubmed/25231400 PubMed] | ||
[[Category:Drug index]] | [[Category:Drug index]] | ||
[[Category:Chemotherapy]] | [[Category:Chemotherapy]] | ||
| − | |||
[[Category:Antibody medications]] | [[Category:Antibody medications]] | ||
[[Category:Anti-mesothelin antibodies]] | [[Category:Anti-mesothelin antibodies]] | ||
| + | |||
| + | [[Category:Mesothelioma medications]] | ||
| + | |||
| + | [[Category:Investigational]] | ||
Revision as of 01:50, 1 January 2016
Mechanism of action
Anti-mesothelin monoclonal antibody
Preliminary data
Mesothelioma
- Hassan R, Kindler HL, Jahan T, Bazhenova L, Reck M, Thomas A, Pastan I, Parno J, O'Shannessy DJ, Fatato P, Maltzman JD, Wallin BA. Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma. Clin Cancer Res. 2014 Dec 1;20(23):5927-36. Epub 2014 Sep 17. link to PMC article PubMed